Trial Profile

A Phase 1, Randomized, Observer-blind, Placebo-controlled, Age De-escalation Study of the Safety, Tolerability, and Immunogenicity of mRNA-1345 and mRNA-1365 in Participants Aged 5 Months to <24 Months

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 04 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA 1365 (Primary) ; MRNA-1345 (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate
Indications Metapneumovirus infections; Respiratory syncytial virus infections
Focus Adverse reactions
Sponsors Moderna Therapeutics

02 Dec 2024 Planned End Date changed from 30 Jul 2026 to 30 Sep 2026.
02 Dec 2024 Planned primary completion date changed from 30 Jul 2026 to 31 Aug 2026.
09 Aug 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com